GlaxoSmithKline PLC ADR - Asset Resilience Ratio
GlaxoSmithKline PLC ADR (GSK) has an Asset Resilience Ratio of 5.58% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of GlaxoSmithKline PLC ADR for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1985–2025)
This chart shows how GlaxoSmithKline PLC ADR's Asset Resilience Ratio has changed over time. See what is GlaxoSmithKline PLC ADR's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down GlaxoSmithKline PLC ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see GlaxoSmithKline PLC ADR (GSK) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $3.40 Billion | 5.57% |
| Short-term Investments | $8.98 Million | 0.01% |
| Total Liquid Assets | $3.41 Billion | 5.58% |
Asset Resilience Insights
- Limited Liquidity: GlaxoSmithKline PLC ADR maintains only 5.58% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
GlaxoSmithKline PLC ADR Industry Peers by Asset Resilience Ratio
Compare GlaxoSmithKline PLC ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AstraZeneca PLC
NASDAQ:AZN |
Drug Manufacturers - General | 5.03% |
|
Novartis AG
MX:NVSN |
Drug Manufacturers - General | 0.09% |
|
Novartis AG ADR
NYSE:NVS |
Drug Manufacturers - General | 10.03% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 7.18% |
|
Virbac SA
PA:VIRP |
Drug Manufacturers - General | 0.23% |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019 |
Drug Manufacturers - General | 0.53% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 8.63% |
Annual Asset Resilience Ratio for GlaxoSmithKline PLC ADR (1985–2025)
The table below shows the annual Asset Resilience Ratio data for GlaxoSmithKline PLC ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.01% | $8.98 Million | $61.01 Billion | -4.65pp |
| 2024-12-31 | 4.66% | $2.77 Billion | $59.46 Billion | -1.80pp |
| 2023-12-31 | 6.46% | $4.86 Billion | $75.22 Billion | -6.63pp |
| 2022-12-31 | 13.10% | $7.88 Billion | $60.15 Billion | +13.02pp |
| 2021-12-31 | 0.08% | $82.62 Million | $107.14 Billion | -0.02pp |
| 2020-12-31 | 0.10% | $106.62 Million | $109.95 Billion | 0.00pp |
| 2019-12-31 | 0.10% | $104.66 Million | $105.57 Billion | -0.05pp |
| 2018-12-31 | 0.14% | $84.00 Million | $58.07 Billion | +0.01pp |
| 2017-12-31 | 0.14% | $78.00 Million | $56.38 Billion | -0.01pp |
| 2016-12-31 | 0.15% | $89.00 Million | $59.08 Billion | +0.01pp |
| 2015-12-31 | 0.14% | $75.00 Million | $53.45 Billion | -0.03pp |
| 2014-12-31 | 0.17% | $69.00 Million | $40.65 Billion | +0.01pp |
| 2013-12-31 | 0.16% | $66.00 Million | $42.09 Billion | -0.04pp |
| 2012-12-31 | 0.20% | $81.00 Million | $41.48 Billion | -0.25pp |
| 2011-12-31 | 0.45% | $184.00 Million | $41.08 Billion | -0.21pp |
| 2010-12-31 | 0.66% | $277.00 Million | $42.05 Billion | -0.27pp |
| 2009-12-31 | 0.93% | $397.00 Million | $42.86 Billion | -0.07pp |
| 2008-12-31 | 0.99% | $391.00 Million | $39.39 Billion | -2.73pp |
| 2007-12-31 | 3.72% | $1.15 Billion | $31.00 Billion | -0.33pp |
| 2006-12-31 | 4.05% | $1.03 Billion | $25.55 Billion | +0.28pp |
| 2005-12-31 | 3.77% | $1.02 Billion | $27.20 Billion | -2.82pp |
| 2004-12-31 | 6.59% | $1.51 Billion | $22.94 Billion | -3.81pp |
| 2003-12-31 | 10.40% | $2.49 Billion | $23.94 Billion | +4.05pp |
| 2002-12-31 | 6.35% | $1.42 Billion | $22.33 Billion | -0.95pp |
| 2001-12-31 | 7.30% | $1.60 Billion | $21.97 Billion | -3.39pp |
| 2000-12-31 | 10.69% | $2.31 Billion | $21.59 Billion | -6.08pp |
| 1999-12-31 | 16.77% | $1.75 Billion | $10.43 Billion | -0.83pp |
| 1998-12-31 | 17.60% | $1.65 Billion | $9.35 Billion | +0.45pp |
| 1997-12-31 | 17.15% | $1.45 Billion | $8.44 Billion | +5.11pp |
| 1996-12-31 | 12.04% | $1.00 Billion | $8.31 Billion | -0.15pp |
| 1995-12-31 | 12.19% | $1.04 Billion | $8.54 Billion | -22.15pp |
| 1993-12-31 | 34.33% | $2.71 Billion | $7.89 Billion | +1.70pp |
| 1992-12-31 | 32.64% | $2.43 Billion | $7.46 Billion | +2.28pp |
| 1991-12-31 | 30.36% | $1.73 Billion | $5.68 Billion | -6.11pp |
| 1990-12-31 | 36.47% | $2.10 Billion | $5.74 Billion | +6.95pp |
| 1989-12-31 | 29.52% | $1.33 Billion | $4.49 Billion | +8.79pp |
| 1988-12-31 | 20.73% | $719.00 Million | $3.47 Billion | -18.76pp |
| 1987-12-31 | 39.48% | $1.13 Billion | $2.87 Billion | +0.81pp |
| 1986-12-31 | 38.68% | $912.00 Million | $2.36 Billion | +7.78pp |
| 1985-12-31 | 30.89% | $557.00 Million | $1.80 Billion | -- |
About GlaxoSmithKline PLC ADR
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more